Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biosimilars
Iceland-based global pureplay biosimilars developer and manufacturer Alvotech announced that its ordinary shares and warrants will begin trading on the Nasdaq Stock Market on Thursday, June 16, under the new ticker symbols “ALVO” and “ALVOW”, respectively. 16 June 2022
Biotechnology
UK drugmaker GSK has welcomed the decision from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to grant Innovation Passport designation to two of its oncology medicines. 16 June 2022
Pharmaceutical
Recordati Rare Diseases, a US biopharma that forms part of the wider Italian group, has presented multiple positive data sets on Isturisa (osilodrostat) at the annual ENDO 2022 meeting in Atlanta, Georgia. 16 June 2022
Biotechnology
US biotech Checkpoint Therapeutics today announced positive interim efficacy results from its registration-enabling clinical trial evaluating its anti-PD-L1 antibody, cosibelimab, in patients with locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation. 16 June 2022
Biotechnology
Swiss drugmaker Roche has announced the results of a trial run in collaboration with Banner Alzheimer’s Institute, the University of Antioquia in Colombia and the National Institute on Aging. 16 June 2022
Pharmaceutical
Aqemia, a next-gen French pharmatech company leveraging artificial intelligence and quantum physics announced, today that it has entered a new research collaboration with pharma major Sanofi. 16 June 2022
Pharmaceutical
Nuplazid (pimavanserin), which is approved for the treatment of Parkinson’s disease psychosis, could struggle to gain a new nod in Alzheimer’s after agency briefing notes revealed doubts over the developer’s submission. 16 June 2022
Biotechnology
Following Tuesday’s scientific recommendation to approve Moderna’s coronavirus vaccine for older children, a panel of experts yesterday endorsed the jab for children as young as six months old. 16 June 2022
Biotechnology
US biotech company Exelixis and Sweden’s BioInvent have entered into an option and license agreement focused on the identification and development of novel antibodies for use in immune-oncology (I-O) therapeutics. 16 June 2022
Biotechnology
Danish CNS specialist Lundbeck announced that the results from the DELIVER study have been recognized for their importance for the scientific and medical community. The results from the clinical study with Vyepti (eptinezumab) were accepted for publication in the prestigious journal Lancet Neurology, one of the most cited medical journals within neurology. 16 June 2022
Biotechnology
India's Central Drugs Standard Control Organization's (CDSCO) oncology/hematology Subject Expert Committee, which advises the drug regulator, has asked the local subsidiary of Swiss pharma giant Roche to submit the efficacy results of its Phase III trial on Tecentriq (atezolizumab), an anti-cancer drug. 16 June 2022
Pharmaceutical
LifeArc and the UK Dementia Research Institute (UK DRI) have today launched a new partnership to accelerate development of new diagnostic tests, treatments, and devices from scientific research discoveries to benefit people with dementia, which around 900,000 people in the UK are living with. 16 June 2022
Pharmaceutical
Japanese drugmaker Shionogi has signed an agreement with the National Health Service (NHS) to begin an innovative subscription payment model reimbursement of cefiderocol in England. 15 June 2022
Pharmaceutical
Boston, USA-based Third Rock Ventures today announced the closing of Third Rock Ventures Fund VI, raising $1.1 billion. 15 June 2022
Biotechnology
Germany’s MorphoSys has entered into an equity participation agreement and license agreements to allow US biotech Human Immunology Biosciences (HIBio) to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. 15 June 2022
Pharmaceutical
US pharma giant Pfizer has provided an update on the latest data on its COVID-19 treatment Paxlovid (nirmatrelvir and ritonavir tablets). 15 June 2022
Pharmaceutical
Shares of Japanese drug major Shionogi closed down 5.6% at 6,493 yen today, despite revealing what it described as a “landmark” collaboration for access to its antibiotic cefiderocol, which is marketed under the trade name Fetroja. 15 June 2022
Pharmaceutical
A couple of European interest groups have issued a joint statement on patient access to medicines for rare diseases. 15 June 2022
Biotechnology
London-listed Finnish biotech firm Faron Pharmaceuticals today announces 12-month top-line overall survival results from its Phase I/II MATINS (Macrophage Antibody To INhibit immune Suppression) study investigating the safety and efficacy of bexmarilimab monotherapy (trade named Clevegen) in 10 different hard-to-treat metastatic or inoperable solid tumor cohorts. 15 June 2022
Biotechnology
A key scientific panel of the US Food and Drug Administration has unanimously voted to recommend approval for Moderna’s COVID-19 vaccine in the age group six to 17. 15 June 2022
All news
Pharmaceutical
The Danish Ministry of Interior and Health has announced that the political parties have decided to permanently legalize treatment with medical cannabis in Denmark. 29 November 2024
Pharmaceutical
The currently available evidence is not sufficient to establish a causal relationship between the use of the antibiotic doxycycline and the risk of suicidality. 29 November 2024
Pharmaceutical
Taiwan-based Formosa Pharmaceuticals (6838: TW) revealed that it has entered into an exclusive licensing agreement with Medvisis Switzerland, in Switzerland and Liechtenstein, for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative treatment of post-operative inflammation and pain following ocular surgery. 29 November 2024
Pharmaceutical
Industry is showing a very high level of readiness for upcoming new packaging and labelling measures impacting the UK market, according to the Medicines and Healthcare products Regulatory Agency (MHRA). 29 November 2024
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal has announced the pricing of 500 million-euro ($527.5 million) aggregate principal amount of 4.625% senior secured notes due 2031. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Pharmaceutical
Germany’s Evotec has said its chief operating officer Craig Johnstone will leave the business at the end of the year. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Pharmaceutical
The waiting time for Latin American patients with cancer, central nervous system disorders or rare diseases can take up to 4.75 years from the time a drug receives approval from global health authorities such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA), until it is approved by their local authority and is available on the market, writes The Pharma Letter's local correspondent. 28 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Pharmaceutical
A new indication for olverembatinib, developed by Suzhou-based Ascentage Pharma will be added to China’s National Reimbursement Drug List (NRDL) from next year. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Pharmaceutical
The first iteration of the European Shortages Monitoring Platform (ESMP) has gone live. 28 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of classic galactosemia, under development by Applied Therapeutics. 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze